Young Hun Chung

Young Hun Chung

Auto-generated profile, based on publicly available information

Young Hun Chung

Department of Bioengineering, University of California San Diego, La Jolla, California 92093, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
MSMatthew D. Shin
Matthew D. Shin
SSSourabh Shukla
Sourabh Shukla
YCYoung Hun Chung
Young Hun Chung
VBVeronique Beiss
Veronique Beiss
SCSoo Khim Chan
Soo Khim Chan
NSNicole Steinmetz
Nicole Steinmetz

9 October 2020 in ACS Nano
Verified
Journal Article
Closed access
YCYoung Hun Chung
Young Hun Chung
VBVeronique Beiss
Veronique Beiss
SFSteven N. Fiering
Steven N. Fiering
NSNicole Steinmetz
Nicole Steinmetz

6 December 2021 in Nature Reviews Materials
Verified
Journal Article
Closed access
PDF file
YCYoung Hun Chung
Young Hun Chung
DCDerek Church
Derek Church
EKEdward C. Koellhoffer
Edward C. Koellhoffer
EOElizabeth Osota
Elizabeth Osota
SSSourabh Shukla
Sourabh Shukla
NSNicole Steinmetz
Nicole Steinmetz

14 September 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
YCYoung Hun Chung
Young Hun Chung
JPJooneon Park
Jooneon Park
HCHui Cai
Hui Cai
NSNicole Steinmetz
Nicole Steinmetz
Prognosis and treatment of metastatic cancer continues to be one of the most difficult and challenging areas of oncology. Treatment usually consists of chemotherapeutics, which may be ineffective due to drug resistance, adverse effects, and dose‐limiting toxicity. Therefore, novel approaches such as immunotherapy have been investigated to improve patient outcomes and minimize side effects. S100A9 is a calcium‐binding protein implicated in tumor metastasis, progression, and aggressiveness that modulates the tumor microenvironment into an immunosuppressive state. S100A9 is expressed in and secreted by immune cells in the pre‐metastatic niche, as well as, post‐tumor development, therefore making it a suitable targeted for prophylaxis and therapy. In previous work, it is demonstrated that cowpea mosaic virus (CPMV) acts as an adjuvant when administered intratumorally. Here, it is demonstrated that systemically administered, S100A9‐targeted CPMV homes to the lungs leading to recruitment of innate immune cells. This approach is efficacious both prophylactically and therapeutically against lung metastasis from melanoma and breast cancer. The current research will facilitate and accelerate the development of next‐generation targeted immunotherapies administered as prophylaxis, that is, after surgery of a primary breast tumor to prevent outgrowth of metastasis, as well as, therapy to treat established metastatic disease.

16 October 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YCYoung Hun Chung
Young Hun Chung
OOOscar Ortega-Rivera
Oscar Ortega-Rivera
BVBritney A. Volckaert
Britney A. Volckaert
EJEunkyeong Jung
Eunkyeong Jung
ZZZhongchao Zhao
Zhongchao Zhao
NSNicole Steinmetz
Nicole Steinmetz
Metastatic cancer accounts for 90% of all cancer-related deaths and continues to be one of the toughest challenges in cancer treatment. A growing body of data indicates that S100A9, a major regulator of inflammation, plays a central role in cancer progression and metastasis, particularly in the lungs, where S100A9 forms a premetastatic niche. Thus, we developed a vaccine against S100A9 derived from plant viruses and virus-like particles. Using multiple tumor mouse models, we demonstrate the effectiveness of the S100A9 vaccine candidates in preventing tumor seeding within the lungs and outgrowth of metastatic disease. The elicited antibodies showed high specificity toward S100A9 without cross-reactivity toward S100A8, another member of the S100A family. When tested in metastatic mouse models of breast cancer and melanoma, the vaccines significantly reduced lung tumor nodules after intravenous challenge or postsurgical removal of the primary tumor. Mechanistically, the vaccines reduce the levels of S100A9 within the lungs and sera, thereby increasing the expression of immunostimulatory cytokines with antitumor function [(interleukin) IL-12 and interferonγ] while reducing levels of immunosuppressive cytokines (IL-10 and transforming growth factorβ). This also correlated with decreased myeloid-derived suppressor cell populations within the lungs. This work has wide-ranging impact, as S100A9 is overexpressed in multiple cancers and linked with poor prognosis in cancer patients. The data presented lay the foundation for the development of therapies and vaccines targeting S100A9 to prevent metastasis.

26 October 2021 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
NCNkanga Christian
Nkanga Christian
YCYoung Hun Chung
Young Hun Chung
SSSourabh Shukla
Sourabh Shukla
JZJingcheng Zhou
Jingcheng Zhou
JJJesse V. Jokerst
Jesse V. Jokerst
NSNicole Steinmetz
Nicole Steinmetz
The coating of tobacco mosaic virus (TMV) nanoparticles Gd-Cy5-TMV with polydopamine (PDA) increased protein corona formation and shortened plasma circulation, but minimized recognition by anti-TMV antibodies, and extended organ distribution/clearance.